[go: up one dir, main page]

WO2007136250A3 - A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition - Google Patents

A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition Download PDF

Info

Publication number
WO2007136250A3
WO2007136250A3 PCT/NL2007/000135 NL2007000135W WO2007136250A3 WO 2007136250 A3 WO2007136250 A3 WO 2007136250A3 NL 2007000135 W NL2007000135 W NL 2007000135W WO 2007136250 A3 WO2007136250 A3 WO 2007136250A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
cancer
preparing
treatment
composition suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2007/000135
Other languages
French (fr)
Other versions
WO2007136250A2 (en
Inventor
Maikel Petrus Peppelenbosch
Maarten Fokke Bijlsma
Christoffel Amoldus Spek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting voor de Technische Wetenschappen STW
Original Assignee
Stichting voor de Technische Wetenschappen STW
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting voor de Technische Wetenschappen STW filed Critical Stichting voor de Technische Wetenschappen STW
Publication of WO2007136250A2 publication Critical patent/WO2007136250A2/en
Publication of WO2007136250A3 publication Critical patent/WO2007136250A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition com- prising an inhibitor of the enzyme 7-dehydrocholesterol reductase (DHCR7) together with a pharmaceutically acceptable carrier or ex- cipient. This pharmaceutical composition is active against various types of cancer, in particular but not limited to adenocarcinomas of the upper gastro-intestinal tract. The invention also relates to a method of preparing a pharmaceutical composition suitable for the treatment of an adenocarcinoma.
PCT/NL2007/000135 2006-05-24 2007-05-24 A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition Ceased WO2007136250A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1031872 2006-05-24
NL1031872 2006-05-24

Publications (2)

Publication Number Publication Date
WO2007136250A2 WO2007136250A2 (en) 2007-11-29
WO2007136250A3 true WO2007136250A3 (en) 2008-03-20

Family

ID=38662919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2007/000135 Ceased WO2007136250A2 (en) 2006-05-24 2007-05-24 A pharmaceutical composition suitable for the treatment of cancer and method of preparing said pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2007136250A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
EP4433445A1 (en) * 2021-11-15 2024-09-25 The Broad Institute, Inc. Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030462A2 (en) * 2000-10-13 2002-04-18 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2004026304A1 (en) * 2002-09-17 2004-04-01 Medical Research Council An inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer
WO2006031977A2 (en) * 2004-09-13 2006-03-23 The Regents Of The University Of California Inhibition of pancreatic cancer cell growth

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030462A2 (en) * 2000-10-13 2002-04-18 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2004026304A1 (en) * 2002-09-17 2004-04-01 Medical Research Council An inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer
WO2006031977A2 (en) * 2004-09-13 2006-03-23 The Regents Of The University Of California Inhibition of pancreatic cancer cell growth

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOIDE TETSUYA ET AL: "Negative regulation of Hedgehog signaling by the cholesterogenic enzyme 7-dehydrocholesterol reductase", DEVELOPMENT (CAMBRIDGE), vol. 133, no. 12, 10 May 2006 (2006-05-10), online publication, pages 2395 - 2405, XP002464601, ISSN: 0950-1991 *
TOKAR E J ET AL: "Vitamin D3 inhibits growth, matrix metalloproteinase activity (MMP) and invasion by RWPE2-W99 human prostate carcinoma cells", CLINICAL & EXPERIMENTAL METASTASIS, XX, XX, vol. 21, no. 7, February 2004 (2004-02-01), pages 607 - 608, XP009094492, ISSN: 0262-0898 *

Also Published As

Publication number Publication date
WO2007136250A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2009027644A3 (en) Compositions for the treatment of neoplastic diseases
WO2003043631A3 (en) Method for identification of tumor targeting enzymes
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
WO2008039829A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2006045119A3 (en) Improved inhibitors for the soluble epoxide hydrolase
WO2007111866A3 (en) Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2007047291A3 (en) Anti-glypican-3 antibody
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
WO2008112565A3 (en) Method and composition for treating cancer
WO2007146426A3 (en) Nanoshells for drug delivery
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007048026A3 (en) Cgrp peptide antagonists and conjugates
WO2008011335A3 (en) Metal binding compounds, metal binding compositions, and their uses
WO2006037981A8 (en) Inhibition of tumour cell migration
WO2008022345A3 (en) Compositions and methods for inhibiting cytochrome p450
WO2007144169A3 (en) Entacapone-derivatives
WO2007084661A3 (en) Therapy-enhancing glucan
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2006096173A8 (en) Pharmaceutical compositions and methods for peptide treatment
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
WO2005105094A3 (en) Cancer treatment method

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07747317

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07747317

Country of ref document: EP

Kind code of ref document: A2